Clinical Trial

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human, dose finding and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C9074 alone and in combination with other anticancer therapies in patients with advanced solid tumors.
Protocol Amendment History 24 amendments
This ClinicalTrials.gov record has been amended 24 times since 2024-01-23; most recent amendment 2026-07-06.
Status change: Not Yet Recruiting → Recruiting 2024-05-06
Trial Details
NCT Number NCT06233942
Lead Sponsor BeOne Medicines
Conditions Advanced Solid Tumor
Enrollment 308 participants
Start Date 2024-04-12
Primary Completion 2027-09-28 (estimated)
Study Completion 2028-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-08